Imatinib, which inhibits the tyrosine kinase activity of BCR-ABL, was introduced as a first-line treatment for chronic myeloid leukemia (CML) almost 10 years ago and radically improved the outcome of patients with CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.